Valerophenone

Valerophenone

SCHEMBL5615151

CCCCC(=O)c1ccccc1.CCCCC(=O)c1ccccc1

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.72
TDP1 Q9NUW8 2/20 0.72
LMNA P02545 1/20 0.72
MAPT P10636 1/20 0.72
HSD17B3 P37058 7/20 0.68
CES2 O00748 2/20 0.66
CES1 P23141 2/20 0.66
HTR7 P34969 1/20 0.66
HDAC1 Q13547 2/20 0.64
HDAC3 O15379 1/20 0.64
HDAC4 P56524 1/20 0.64
HDAC7 Q8WUI4 1/20 0.64
HDAC2 Q92769 1/20 0.64
HDAC10 Q969S8 1/20 0.64
HDAC11 Q96DB2 1/20 0.64
HDAC8 Q9BY41 1/20 0.64
HDAC6 Q9UBN7 1/20 0.64
HDAC9 Q9UKV0 1/20 0.64
HDAC5 Q9UQL6 1/20 0.64
NPC1 O15118 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Valerophenone SCHEMBL50014 1.00 L3MBTL1 (0.72) L3MBTL1TDP1LMNAMAPTHSD17B3
Valerophenone SCHEMBL9725402 1.00 L3MBTL1 (0.72) L3MBTL1TDP1LMNAMAPTHSD17B3
Valerophenone SCHEMBL27921461 0.98 L3MBTL1 (0.69) L3MBTL1TDP1LMNAMAPTHSD17B3
Valerophenone SCHEMBL9858470 0.98 L3MBTL1 (0.69) L3MBTL1TDP1LMNAMAPTHSD17B3
SCHEMBL9725525 0.94 L3MBTL1 (0.76) L3MBTL1TDP1LMNAMAPTHSD17B3
SCHEMBL50000 0.94 L3MBTL1 (0.76) L3MBTL1TDP1LMNAMAPTHSD17B3
SCHEMBL962630 0.92 L3MBTL1 (0.80) L3MBTL1TDP1LMNAMAPTHSD17B3
SCHEMBL967963 0.92 L3MBTL1 (0.80) L3MBTL1TDP1LMNAMAPTHSD17B3
SCHEMBL964590 0.92 L3MBTL1 (0.80) L3MBTL1TDP1LMNAMAPTHSD17B3
SCHEMBL22528986 0.92 L3MBTL1 (0.80) L3MBTL1TDP1LMNAMAPTHSD17B3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-7288677-B2 Diimines and secondary diamines ALBEMARLE CORPORATION (US) 2007-10-30 US disclosed
US-20060217567-A1 Diimines and secondary diamines ALBEMARLE CORPORATION 2006-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217567-A1 Diimines and secondary diamines DDT, DDC, AOC1 L3MBTL1 2969/4885TDP1 1225/4885LMNA 3166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.